TP53 Gene Mutations Predict the Response to Neoadjuvant Treatment with 5-Fluorouracil and Mitomycin in Locally Advanced Breast Cancer

Clinical Cancer Research

Volumn 9, Issue 15, 2003, Pages 5582-5588

  Geisler, Stephanie ^a   Børresen Dale, Anne Lise ^c   Johnsen, Hilde ^c   Aas, Turid ^b   Geisler, Jürgen ^a   Akslen, Lars Andreas ^b   Anker, Gun ^a   Lønning, Per Eystein ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GENOMIC DNA; MITOMYCIN; PROTEIN P53; TAMOXIFEN;

ADULT; ADVANCED CANCER; AGED; AMINO ACID SUBSTITUTION; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL PROTOCOL; CORRELATION ANALYSIS; DRUG DOSE REGIMEN; FEMALE; FRAMESHIFT MUTATION; GENE; GENE DELETION; GENE INSERTION; GENE MUTATION; GENE SEQUENCE; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MISSENSE MUTATION; MUTATIONAL ANALYSIS; NONSENSE MUTATION; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; SURVIVAL RATE; TP53 GENE; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; FLUOROURACIL; GENES, P53; HUMANS; LOSS OF HETEROZYGOSITY; MIDDLE AGED; MITOMYCIN; MUTATION; PREDICTIVE VALUE OF TESTS;

EID: 0344198117     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Kerr, J. F., Winterford, C. M., and Harmon, B. V. Apoptosis. Its significance in cancer and cancer therapy. Cancer (Phila.), 73: 2013-2026, 1994.
2. Ellis, P. A., Smith, I. E., McCarthy, K., Detre, S., Salter, J., and Dowsett, M. Preoperative chemotherapy induces apoptosis in early breast cancer. Lancet, 349: 849, 1997.
3. Bergh, J., Norberg, T., Sjogren, S., Lindgren, A., and Holmberg, L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat. Med., 1: 1029-1034, 1995.
4. Borresen, A. L., Andersen, T. I., Eyfjord, J. E., Cornelis, R. S., Thorlacius, S., Borg, A., Johansson, U., Theillet, C., Scherneck, S., Hartman, S., et al. TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes Cancer, 14: 71-75, 1995.
5. Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957-967, 1993.
6. Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., and Jacks, T. p53 status and the efficacy of cancer therapy in vivo. Science (Wash. DC), 266: 807-810, 1994.
7. Fisher, C. J., Gillett, C. E., Voitèsek, B., Barnes, D. M., and Millis, R. R. Problems with p53 immunohistochemical staining: the effect of fixation and variation in the methods of evaluation. Br. J. Cancer, 69: 26-31, 1994.
8. Archer, S. G., Eliopoulos, A., Spandidos, D., Barnes, D., Ellis, I. O., Blamey, R. W., Nicholson, R. I., and Robertson, J. F. Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br. J. Cancer, 72: 1259-1266, 1995.
9. Elledge, R. M., Green, S., Howes, L., Clark, G. M., Berardo, M., Allred, D. C., Pugh, R., Ciocca, D., Ravdin, P., O'Sullivan, J., Rivkin, S., Martino, S., and Osborne, C. K. bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study. J. Clin. Oncol., 15: 1916-1922, 1997.
10. Niskanen, E., Blomqvist, C., Franssila, K., Hietanen, P., and Wasenius, V. M. Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer. Br. J. Cancer, 76: 917-922, 1997.
11. Jarvinen, T. A., Holli, K., Kuukasjarvi, T., and Isola, J. J. Predictive value of topoisomerase IIα and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br. J. Cancer, 77: 2267-2273, 1998.
12. Rozan, S., Vincent-Salomon, A., Zafrani, B., Validire, P., De Cremoux, P., Bernoux, A., Nieruchalski, M., Fourquet, A., Clough, K., Dieras, V., Pouillart, P., and Sastre-Garau, X. No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int. J. Cancer, 79: 27-33, 1998.
13. Muss, H. B., Thor, A. D., Berry, D. A., Kute, T., Liu, E. T., Koerner, F., Cirrincione, C. T., Budman, D. R., Wood, W. C., Barcos, M., et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N. Engl. J. Med., 330: 1260-1266, 1994.
14. Jacquemier, J., Penault-Llorca, F., Viens, P., Houvenaeghel, G., Hassoun, J., Torrente, M., Adelaide, J., and Birnbaum, D. Breast cancer response to adjuvant chemotherapy in correlation with erbB2 and p53 expression. Anticancer Res., 14: 2773-2778, 1994.
15. Elledge, R. M., Gray, R., Mansour, E., Yu, Y., Clark, G. M., Ravdin, P., Osborne, C. K., Gilchrist, K., Davidson, N. E., Robert, N., et al. Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J. Natl. Cancer Inst. (Bethesda), 87: 1254-1256, 1995.
16. Degeorges, A., de Roquancourt, A., Extra, J. M., Espie, M., Bourstyn, E., de Cremoux, P., Soussi, T., and Marty, M. Is p53 a protein that predicts the response to chemotherapy in node negative breast cancer? Breast Cancer Res. Treat., 47: 47-55, 1998.
17. Makris, A., Powles, T. J., Dowsett, M., Osborne, C. K., Trott, P. A., Fernando, I. N., Ashley, S. E., Ormerod, M. G., Titley, J. C., Gregory, R. K., and Allred, D. C. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin. Cancer Res., 3: 593-600, 1997.
18. MacGrogan, G., Mauriac, L., Durand, M., Bonichon, F., Trojani, M., de Mascarel, I., and Coindre, J. M. Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST π. Br. J. Cancer, 74: 1458-1465, 1996.
19. Dublin, E. A., Miles, D. W., Rubens, R. D., Smith, P., and Barnes, D. M. p53 immunohistochemical staining and survival after adjuvant chemotherapy for breast cancer. Int. J. Cancer, 74: 605-608, 1997.
20. Linn, S. C., Pinedo, H. M., van Ark-Otte, J., van der Valk, P., Hoekman, K., Honkoop, A. H., Vermorken, J. B., and Giaccone, G. Expression of drug resistance proteins in breast cancer, in relation to chemotherapy. Int. J. Cancer, 71: 787-795, 1997.
21. Bonetti, A., Zaninelli, M., Leone, R., Cetto, G. L., Pelosi, G., Biolo, S., Menghi, A., Manfrin, E., Bonetti, F., and Piubello, Q. bcl-2 but not p53 expression is associated with resistance to chemotherapy in advanced breast cancer. Clin. Cancer Res., 4: 2331-2336, 1998.
22. Geisler, S., Lonning, P. E., Aas, T., Johnsen, H., Fluge, O., Haugen, D. F., Lillehaug, J. R., Akslen, L. A., and Borresen-Dale, A. L. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res., 61: 2505-2512, 2001.
23. Soussi, T., and Beroud, C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat. Rev. Cancer, 1: 233-240, 2001.
24. Aas, T., Borresen, A. L., Geisler, S., Smith-Sorensen, B., Johnsen, H., Varhaug, J. E., Akslen, L. A., and Lonning, P. E. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat. Med., 2: 811-814, 1996.
25. Kandioler-Eckersberger, D., Ludwig, C., Rudas, M., Kappel, S., Janschek, E., Wenzel, C., Schlagbauer-Wadl, H., Mittlbock, M., Gnant, M., Steger, G., and Jakesz, R. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin. Cancer Res., 6: 50-56, 2000.
26. Wattel, E., Preudhomme, C., Hecquet, B., Vanrumbeke, M., Quesnel, B., Dervite, I., Morel, P., and Fenaux, P. p53 mutations are associated with resistance to chemotherapy and short survival in hematological malignancies. Blood, 84: 3148-3157, 1994.
27. Preudhomme, C., Dervite, I., Wattel, E., Vanrumbeke, M., Flactif, M., Lai, J. L., Hecquet, B., Coppin, M. C., Nelken, B., Gosselin, B., et al. Clinical significance of p53 mutations in newly diagnosed Burkitt's lymphoma and acute lymphoblastic leukemia: a report of 48 cases. J. Clin. Oncol., 13: 812-820, 1995.
28. Ichikawa, A., Kinoshita, T., Watanabe, T., Kato, H., Nagai, H., Tsushita, K., Saito, H., and Hotta, T. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N. Engl. J. Med., 337: 529-534, 1997.
29. Page, D. L., Ellis, I. O., and Elston, C. W. Histologic grading of breast cancer. Let's do it. Am. J. Clin. Pathol, 103: 123-124, 1995.
30. Hayward, J. L., Rubens, R. D., Carbone, P. P., Heuson, J-C., Kumaoka, S., and Segaloff, A. Assessment of response to therapy in advanced breast cancer. Br. J. Cancer, 35: 292-298, 1977.
31. Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., Van Oosterom, A. T., Christian, M. C., and Gwyther, S. G. New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst. (Bethesda), 92: 205-216, 2000.
32. Lonning, P. E. Study of suboptimum treatment response: lessons from breast cancer. Lancet Oncol., 4: 177-185, 2003.
33. Sorlie, T., Vu, P., Johnsen, H., Lind, G. E., Lothe, R. A., and Børresen-Dale, A. L. Protocol for mutation screening of the TP53 gene by temporal temperature gel electrophoresis (TTGE). In: Methods in Molecular Biology, Methods for Detecting and Characterizing Genetic Alterations. Totowa, NJ: Humana Press, in press, 2003.
34. Borresen, A. L. Constant denaturant gel electrophoresis (CDGE) in mutation screening. In: G. P. Pfeifer (ed.), Technologies for Detection of DNA Damage and Mutation, pp. 267-279. New York: Plenum Press, 1996.
35. Hahn, M., Serth, J., Fislage, R., Wolfes, H., Allhoff, E., Jonas, V., and Pingoud, A. Polymerase chain reaction detection of a highly polymorphic VNTR segment in intron 1 of the human p53 gene. Clin. Chem, 39: 549-550, 1993.
36. Jones, M. H., and Nakamura, Y. Detection of loss of heterozygosity at the human TP53 locus using a dinucleotide repeat polymorphism. Genes Chromosomes Cancer, 5: 89-90, 1992.
37. Sjogren, S., Inganas, M., Norberg, T., Lindgren, A., Nordgren, H., Holmberg, L., and Bergh, J. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J. Natl. Cancer Inst. (Bethesda), 88: 173-182, 1996.
38. Formenti, S. C., Dunnington, G., Uzieli, B., Lenz, H., Keren-Rosenberg, S., Silberman, H., Spicer, D., Denk, M., Leichman, G., Groshen, S., Watkins, K., Muggia, F., Florentine, B., Press, M., Danenberg, K., and Danenberg, P. Original p53 status predicts for pathological response in locally advanced breast cancer patients treated preoperatively with continuous infusion 5-fluorouracil and radiation therapy. Int. J. Radiat Oncol Biol. Phys., 39: 1059-1068, 1997.
39. Lizard-Nacol, S., Coudert, B., Riedinger, J. M., Fargeot, P., and Guerrin, J. p53 gene alterations are associated with a decreased responsiveness to neoadjuvant chemotherapy in human breast cancer. Int. J. Oncol., 10: 1203-1207, 1997.
40. Berns, E. M., Foekens, J. A., Vossen, R., Look, M. P., Devilee, P., Henzen-Logmans, S. C., van Staveren, I. L., van Putten, W. L., Inganas, M., Meijer-van Gelder, M. E., Cornelisse, C., Claassen, C. J., Portengen, H., Bakker, B., and Klijn, J. G. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res., 60: 2155-2162, 2000.
41. Mattsson, W., von Eyben, F., Hallsten, L., and Bjelkengren, G. A Phase II study of combined 5-fluorouracil and mitomycin C in advanced breast cancer. Cancer (Phila.), 49: 217-220, 1982.
42. Gundersen, S., Kvinnsland, S., Klepp, O., Lund, E., Hannisdal, E., and Høst, H. Chemotherapy with or without medroxyprogesterone acetate in oestrogen-receptor-negative advanced breast cancer. Eur. J. Cancer, 28: 390-394, 1992.
43. Santi, D. V., McHenry, C. S., Raines, R. T., and Ivanetich, K. M. Kinetics and thermodynamics of the interaction of 5-fluoro-2′ -deoxyuridylate and thymidylate synthase. Biochemistry, 26: 8606-8613, 1987.
44. Kufe, D. W., and Major, P. P. 5-Fluorouracil incorporation into human breast carcinoma RNA correlates with cytotoxicity. J. Biol. Chem., 256: 9802, 1981.
45. Takimoto, C. H., Voeller, D. B., Strong, J. M., Anderson, L., Chu, E., and Allegra, C. J. Effects of 5-fluorouracil substitution on the RNA conformation and in vitro translation of thymidylate synthase messenger RNA. J. Biol. Chem., 268: 21438-21442, 1993.
46. Bizanek, R., McGuinness, B. F., Nakanishi. K., and Tomasz, M. Isolation and structure of an intrastrand cross-link adduct of mitomycin C and DNA. Biochemistry, 31: 3084-3091, 1992.
47. Bizanek, R., Chowdary, D., Arai, H., Kasai, M., Hughes, C. S., Sartorelli, A. C., Rockwell, S., and Tomasz, M. Adducts of mitomycin C and DNA in EMT6 mouse mammary tumor cells: effects of hypoxia and dicumarol on adduct patterns. Cancer Res., 53: 5127-5134, 1993.
48. 32P-postlabeling. Clin. Cancer Res., 7: 1033-1042, 2001.
49. Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., and Vogelstein, B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Investig., 104: 263-269, 1999.
50. Cabelguenne, A., Blons, H., de Waziers, I., Carnot, F., Houllier, A. M., Soussi, T., Brasnu, D., Beaune, P., Laccourreye, O., and Laurent-Puig, P. p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. J. Clin. Oncol., 18: 1465-1473, 2000.
51. Lynn, N. N., Howe, M. C., Hale, R. J., Collins, G. N., and O'Reilly, P. H. Over expression of metallothionein predicts resistance of transitional cell carcinoma of bladder to intravesical mitomycin therapy. J. Urol., 169: 721-723, 2003.
52. Noutomi, T., Chiba, H., Itoh, M., Toyota, H., and Mizuguchi, J. Bcl-x(L) confers multi-drug resistance in several squamous cell carcinoma cell lines. Oral Oncol, 38: 41-48, 2002.
53. Hayes, M. C., Birch, B. R., Cooper, A. J., and Primrose, J. N. Cellular resistance to mitomycin C is associated with overexpression of MDR-1 in a urothelial cancer cell line (MGH-U1). BJU Int., 87: 245-250, 2001.
54. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991.
55. Inoue, T., Geyer, R. K., Yu, Z. K., and Maki, C. G. Downregulation of MDM2 stabilizes p53 by inhibiting p53 ubiquitination in response to specific alkylating agents. FEBS Lett., 490: 196-201, 2001.
56. Abbas, T., Olivier, M., Lopez, J., Houser, S., Xiao, G., Kumar, G. S., Tomasz, M., and Bargonetti, J. Differential activation of p53 by the various adducts of mitomycin C. J. Biol. Chem., 277: 40513-40519, 2002.
57. Flaman, J. M., Robert, V., Lenglet, S., Moreau, V., Iggo, R., and Frebourg, T. Identification of human p53 mutations with different effects on the bax and p21 promoters using functional assays in yeast. Oncogene, 16: 1369-1372, 1998.
58. Di Como, C. J., and Prives, C. Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay. Oncogene, 16: 2527-2539, 1998.
59. Monti, P., Campomenosi, P., Ciribilli, Y., Iannone, R., Inga, A., Abbondandolo, A., Resnick, M., and Fronza, G. Tumour p53 mutations exhibit promoter selective dominance over wild type p53. Oncogene, 21: 1641-1648, 2002.
60. Cho, Y., Gorina, S., Jeffrey, P. D., and Pavletich, N. P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science (Wash. DC), 265: 346-355, 1994.
61. Allred, D. C., Clark, G. M., Elledge, R., Fuqua, S. A., Brown, R. W., Chamness, G. C., Osborne, C. K., and McGuire, W. L. Association of the p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J. Natl. Cancer Inst. (Bethesda), 3: 200-206, 1993.
62. Bottini, A., Berruti, A., Bersiga, A., Brizzi, M. P., Brunelli, A., Gorzegno, G., DiMarco, B., Aguggini, S., Bolsi, G., Cirillo, F., Fillippini, L., Betri, E., Bertoli, G., Alquati, P., and Dogliotti, L. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Clin. Cancer Res., 6: 2751-2758, 2000.
63. van Slooten, H. J., van De Vijver, M. J., Borresen, A. L., Eyfjord, J. E., Valgardsdottir, R., Scherneck, S., Nesland, J. M., Devilee, P., Cornelisse, C. J., and van Dierendonck, J. H. Mutations in exons 5-8 of the p53 gene, independent of their type and location, are associated with increased apoptosis and mitosis in invasive breast carcinoma. J. Pathol., 189: 504-513, 1999.
64. Yang, Q. F., Sakurai, T., Yoshimura, G., Shan, L., Suzuma, T., Tamaki, T., Umemura, T., Kokawa, Y., Nakamura, Y., Nakamura, M., Tang, W., Utsunomiya, H., Mori, I., and Kakudo, K. Expression of Bcl-2 but not Bax or p53 correlates with in vitro resistance to a series of anticancer drugs in breast carcinoma. Breast Cancer Res. Treat., 61: 211-216, 2000.
65. Aas, T., Geisler, S., Eide, G. E., Faksvåg Haugen, D., Varhaug, J. E., Bassøe, A. M., Thorsen, T., Berntsen, H., Borresen-Dale, A., Lonning, P. E., and Akslen, L. A. Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy. Eur. J. Cancer, 39: 438-446, 2002.